PipelineReview.com4h
CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
SHANGHAI, China I7, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for ...
PipelineReview.com4h
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
DONGGUAN, China I February 28, 2025 I Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce ...
PipelineReview.com20h
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for “IO 2.0 + ADC” Strategy
HONG KONG, China I7, 2025 I Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the ...
PipelineReview.com20h
Hemab Therapeutics Announces Start of Velora Pioneer, a Phase 1/2 Clinical Trial Investigating HMB-002 for the Treatment of Von Willebrand Disease
First participant with Von Willebrand Disease dosed with HMB-002, a novel subcutaneous therapy designed to increase endogenous von Willebrand Factor and ...